271 articles · 20 / page
This phase 1 trial identifies APG-2449 as a potent ALK/ROS1/FAK inhibitor. It shows significant efficacy in TKI-naïve and second-generation TKI-resistant ALK+ NSCLC, with high blood-brain barrier penetration and a manageable safety profile,
The final analysis of the Phase III ALEX trial confirms alectinib’s superior long-term efficacy over crizotinib, achieving a median overall survival of 81.1 months and significant intracranial benefits, solidifying its role as the fir
A landmark study of over 18,000 patients reveals that sarcoidosis incidence and prevalence in England are rising, particularly among older adults. With a 36% higher mortality risk compared to the general population, these findings demand a
This review synthesizes the findings of the PROVID randomized clinical trial and broader literature, demonstrating that awake prone positioning (APP) significantly reduces the probability of intubation and death in patients with COVID-19 hy
A massive cohort study of 11.3 million US veterans reveals that obstructive sleep apnea is an independent risk factor for Parkinson disease, but early treatment with CPAP significantly reduces this risk, particularly in women.
This review analyzes the long-term effectiveness of RSV vaccination among US Veterans, revealing significant protection against severe outcomes that wanes over two seasons, particularly in immunocompromised populations.
Recent evidence reveals that COPD in adults under 50 is more prevalent than previously thought, significantly increasing the risk of premature death and heart failure. Furthermore, impaired lung function trajectories starting in childhood p
The MULTI-CAP trial demonstrated that combining multiplex PCR and procalcitonin did not significantly increase the number of antibiotic-free days by Day 28 in ICU patients with pneumonia, although it did successfully reduce the cumulative d
The OPTIC-2 phase 3b trial confirms that omadacycline is noninferior to moxifloxacin for treating community-acquired bacterial pneumonia (CABP). This once-daily aminomethylcycline offers a robust IV-to-oral monotherapy option with a favorab
A reanalysis of the ICAR trial reveals that ARDS inflammatory subphenotypes remain remarkably stable over 28 days. The hyperinflammatory profile is linked to higher mortality and distinct biomarkers, with Bayesian modeling showing minimal t
A groundbreaking study utilizing an AI classifier demonstrates that ARDS inflammatory phenotypes are dynamic and dictate corticosteroid efficacy. While hyperinflammatory patients benefit from steroids, hypoinflammatory patients face increas
A rigorous multicenter study from Japan utilizes marginal structural modeling to demonstrate that Ventilator-Associated Events (VAEs) are independent drivers of mortality, not just surrogates for patient severity, reinforcing their value as
The DANFLU-2 trial demonstrates that high-dose influenza vaccine provides superior protection against influenza-related hospitalizations in chronic kidney disease and reduces cardiorespiratory hospitalizations in older adults irrespective o
A randomized trial demonstrates that a smartphone app-based pulmonary rehabilitation program significantly improves quality of life and physical activity in patients with chronic respiratory diseases, offering a scalable alternative to trad
A 12-week randomized controlled trial reveals that smartphone-based pulmonary rehabilitation significantly improves quality of life and physical activity in patients with chronic respiratory diseases, offering a scalable and feasible altern
A randomized trial demonstrates that continuous erector spinae plane block provides comparable analgesia to opioid regimens after VATS, while significantly improving patient recovery scores and reducing postoperative complications.
The FDA has approved depemokimab (Exdensur), the first long-acting biologic for severe eosinophilic asthma. Requiring only two doses per year, it significantly reduces exacerbations and hospitalizations, offering a transformative shift in t
The DANFLU-2 trial found that while high-dose influenza vaccines significantly reduced influenza-specific hospitalizations in older adults, they did not reach statistical significance for the combined primary endpoint of influenza or pneumo
A 2025 Cochrane update (3 RCTs, 368 infants) finds very low- to low-certainty evidence that HFOV neither clearly reduces treatment failure nor pulmonary air leak and may increase mortality versus conventional ventilation in term/near‑term i
This review examines the safety and effectiveness of electronic cigarettes as aids to quit smoking, showing increased abstinence rates compared to traditional therapies and no significant serious adverse events reported.
Open language-specific specialty feeds and department pages.